4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine trihydrochloride

• ChemBase编号: 132860
• 分子式: C18H22Cl3FN6
• 平均质量: 447.7648832
• 单一同位素质量: 446.09555599
• SMILES: c1cc(ccc1c1c(n(cn1)C1CCNCC1)c1ccnc(n1)N)F.Cl.Cl.Cl
• Canonical SMILES: Nc1nccc(n1)c1n(cnc1c1ccc(cc1)F)C1CCNCC1.Cl.Cl.Cl
• InChI: InChI=1S/C18H19FN6.3ClH/c19-13-3-1-12(2-4-13)16-17(15-7-10-22-18(20)24-15)25(11-23-16)14-5-8-21-9-6-14;;;/h1-4,7,10-11,14,21H,5-6,8-9H2,(H2,20,22,24);3*1H
• InChIKey: IPFBHUGKKONHFR-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine trihydrochloride
• IUPAC传统名: 4-[5-(4-fluorophenyl)-3-(piperidin-4-yl)imidazol-4-yl]pyrimidin-2-amine trihydrochloride
• 别名: 5-(2-Aminopyrimidin-4-yl)-4-(4-fluorophenyl)-1-(4-piperidinyl)imidazole trihydrochloride; SB 220025 trihydrochloride

登记号

• CAS号: 197446-75-6
• MDL号: MFCD08705333
• PubChem SID: 24724623; 162227137
• PubChem CID: 16079013

理论计算性质

• Acid pKa: 16.378748
• 质子受体: 5
• 质子供体: 2
• LogD (pH = 5.5): -1.5171407
• LogD (pH = 7.4): -0.83588886
• Log P: 1.7774142
• 摩尔折射率: 94.9989 cm^3
• 极化性: 37.97174 Å^3
• 极化表面积: 81.65 Å^2
• 可自由旋转的化学键: 3
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: H2O: soluble22 mg/mL
• 外观: white solid

安全信息

• 欧盟危险性物质标志: 有毒(Toxic) (T)
• 联合国危险货物编号: 2811
• 德国WGK号: 3
• 联合国危险货物等级: 6.1
• 联合国危险货物包装类别(PG): 3
• 危险公开号: 25-36/37/38
• 安全公开号: 26-36-45
• GHS危险品标识: GHS06
• GHS警示词: Danger
• GHS危险声明: H301-H315-H319-H335
• GHS警示性声明: P261-P301 + P310-P305 + P351 + P338
• 个人保护装置: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
• RID/ADR: UN 2811 6.1/PG 3

产品相关信息

• 纯度: ≥98% (HPLC)

详细说明

Sigma Aldrich - S9070

Biochem/physiol Actions
SB 220025 is a potent, specific inhibitor of human p38 mitogen-activated protein (MAP) kinase, with an IC50 value of 60 nM and 50- to 1000-fold selectivity. SB 220025 reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 reduced the lipopolysaccharide-induced production of TNF at an ED50 value of 7.5 mg/kg. At 30 mg/kg, SB 220025 reduced the expression of TNF and inhibited angiogenesis by ~40%. In a further study, the effects of p38/CSBP MAP kinase inhibition in angiogenesis-dependent chronic inflammatory disease was tested in murine collagen-induced arthritis and SB 220025 was able to prevent the progression of established arthritis.